BioSpace News Archive

Business

Medtronic CEO Talks Value-Based Care, Addresses Criticism of M&A Strategy at JPM

In his opening presentation at JPM, he highlighted one major product to show how the Irish medtech company is pursuing value-based care.

January 9, 2018
·
1 min read
Biotech Beach

Crown Bioscience Launches CrownSyn, an Innovative Bioinformatics Solution that Simplifies the Characterization of Two-Drug Combination Studies

CrownSyn is now available as an add-on feature to all two-drug combinatorial studies conducted by Crown Bioscience.

January 9, 2018
·
2 min read
Business

Ally Bridge and LifeTech Scientific Join to Invest in MedTech Companies

The two companies will invest as partners in global medtech enterprises with the goal of accelerating their market entry and commercialization in China.

January 9, 2018
·
1 min read
Drug Development

Axovant’s Nightmare Week Continues After CEO Admits Numbers Were Even Worse Than Reported Yesterday

Vivek Ramaswamy’s Axovant has egg on its face after it was forced to own up to the fact it misreported mid-stage data on a drug it hoped to take into Phase III.

January 9, 2018
·
2 min read
·
Alex Keown
Biotech Beach

5 Top Biotech Stocks That Look Vulnerable in 2018

Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.

January 9, 2018
·
3 min read
·
Mark Terry
Lepu Medical Pays $23.3M for 13% Stake in Australia’s Viralytics

Viralytics will use the funds for an Australian Phase III trial of CAVATAK, its oncolytic immunotherapy based on a common cold virus.

January 9, 2018
·
1 min read
Business

Adaptimmune’s CMO Moves Forward With SPEAR T Cell Therapies

Adaptimmune is making strides on becoming a fully integrated cell therapy company behind its T Cell Receptor technology

January 9, 2018
·
3 min read
·
Alex Keown
Shire to Break Up Business Into Two Companies

Shire is splitting into two separate internal business units, Rare Disease Division and Neuroscience Division.

January 9, 2018
·
2 min read
·
Mark Terry
Deals

Why Pfizer Could and Should Make Another Move on Allergan

Since the acquisition fell apart, Allergan has fallen on some hard times.

January 9, 2018
·
2 min read
·
Alex Keown
Business

Jobs Lost as Cellectar Biosciences Shutters Manufacturing Operations

Cellectar Biosciences is closing its manufacturing operations and contracting them out.

January 9, 2018
·
2 min read
·
Mark Terry